Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 10/20 | 0.51 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.48 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144167 | 0.94 | RIPK2 (0.50) | RIPK2BRPF1CREBBPCECR2BRD9 | |
| SCHEMBL3149111 | 0.89 | MAPK14 (0.52) | RIPK2BRPF1CREBBPCECR2BRD9 | |
| SCHEMBL3145569 | 0.86 | MAPK14 (0.50) | RIPK2BRPF1CREBBPCECR2BRD9 | |
| SCHEMBL3148553 | 0.84 | MAPK14 (0.54) | MAPK14LCKKITKDRTTK | |
| SCHEMBL3141848 | 0.82 | MAPK13 (0.50) | MAPK14MAPK13 | |
| SCHEMBL3148991 | 0.82 | MAPK14 (0.49) | MAPK14LCKKITKDR | |
| SCHEMBL3138765 | 0.81 | MAPK14 (0.49) | RIPK2MAPK14 | |
| SCHEMBL3144145 | 0.81 | MAPK14 (0.53) | MAPK14HPGD | |
| SCHEMBL3144069 | 0.80 | MAPK14 (0.54) | RIPK2BRPF1CREBBPCECR2BRD9 | |
| SCHEMBL3150192 | 0.80 | MAPK14 (0.46) | MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699800-B1 | BICYCLIC HETEROCYCLIC P-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-02-10 | — | — | EP | claimed |
| EP-1699800-B1 | BICYCLIC HETEROCYCLIC P-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-02-10 | — | — | EP | disclosed |
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | DONG QING | 2009-10-22 | — | — | US | disclosed |
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | DONG QING | 2009-10-22 | — | — | US | disclosed |
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | DONG QING | 2009-10-22 | — | — | US | disclosed |
| US-7569571-B2 | Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-7569571-B2 | Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-7569571-B2 | Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | TRIAD THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | TRIAD THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | TRIAD THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | MAPK8, MAP3K8, MAPKAPK2 | RIPK2 457/4885BRPF1 1083/4885CREBBP 170/4885 |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | MAPK1, MAP3K8, MAP3K1 | RIPK2 338/4885BRPF1 1132/4885CREBBP 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.